MANGIA, S., Alena SVÁTKOVÁ, D. MASCALI, M.J. NISSI, P.C. BURTON, Petr BEDNAŘÍK, E.J. AUERBACH, F. GIOVE, L.E. EBERLY, M.J. HOWELL, Igor NESTRAŠIL, P.J. TUITE and S. MICHAELI. Multi-moral Brain MRI in subjects with PD and iRBD (Multi-modal brain MRI in subjects with PD and iRBD). Frontiers in Neuroscience. Lausanne: Frontiers Media S.A., 2017, vol. 11, DEC, p. 709-720. ISSN 1662-453X. Available from: https://dx.doi.org/10.3389/fnins.2017.00709.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Multi-moral Brain MRI in subjects with PD and iRBD
Authors MANGIA, S. (840 United States of America), Alena SVÁTKOVÁ (703 Slovakia, belonging to the institution), D. MASCALI (380 Italy), M.J. NISSI (246 Finland), P.C. BURTON (840 United States of America), Petr BEDNAŘÍK (203 Czech Republic, guarantor, belonging to the institution), E.J. AUERBACH (840 United States of America), F. GIOVE (380 Italy), L.E. EBERLY (840 United States of America), M.J. HOWELL (840 United States of America), Igor NESTRAŠIL (203 Czech Republic), P.J. TUITE (380 Italy) and S. MICHAELI (840 United States of America).
Edition Frontiers in Neuroscience, Lausanne, Frontiers Media S.A. 2017, 1662-453X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30103 Neurosciences
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.877
RIV identification code RIV/00216224:14740/17:00098682
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.3389/fnins.2017.00709
UT WoS 000418300300002
Keywords in English rotating frame MRI; Parkinson's disease; iRBD; functional connectivity; DTI
Tags OA, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Pavla Foltynová, Ph.D., učo 106624. Changed: 6/3/2018 09:14.
Abstract
Idiopathic rapid eye movement sleep behavior disorder (iRBD) is a condition that often evolves into Parkinson's disease (PD). Therefore, by monitoring iRBD it is possible to track the neurodegeneration of individuals who may progress to PD. Here we aimed at piloting the characterization of brain tissue properties in mid-brain subcortical regions of 10 healthy subjects, 8 iRBD, and 9 early-diagnosed PD. We used a battery of magnetic resonance imaging (MRI) contrasts at 3T, including adiabatic and non-adiabatic rotating frame techniques developed by our group, along with diffusion tensor imaging (DTI) and resting-state fMRI. Adiabatic T1(rho) and T2(rho), and non-adiabatic RAFF4 (Relaxation Along a Fictitious Field in the rotating frame of rank 4) were found to have lower coefficient of variations and higher sensitivity to detect group differences as compared to DTI parameters such as fractional anisotropy and mean diffusivity. Significantly longer T1(rho) were observed in the amygdala of PD subjects vs. controls, along with a trend of lower functional connectivity as measured by regional homogeneity, thereby supporting the notion that amygdalar dysfunction occurs in PD. Significant abnormalities in reward networks occurred in iRBD subjects, who manifested lower network strength of the accumbens. In agreement with previous studies, significantly longer T1(rho) occurred in the substantia nigra compacta of PD vs. controls, indicative of neuronal degeneration, while regional homogeneity was lower in the substantia nigra reticulata. Finally, other trend-level findings were observed, i.e., lower RAFF4 and T2(rho) in the midbrain of iRBD subjects vs. controls, possibly indicating changes in non-motor features as opposed to motor function in the iRBD group. We conclude that rotating frame relaxation methods along with functional connectivity measures are valuable to characterize iRBD and PD subjects, and with proper validation in larger cohorts may provide pathological signatures of iRBD and PD.
Links
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
691110, interní kód MUName: Advanced MR methods for characterization of microstructural brain damage (MICROBRADAM) (Acronym: MICROBRADAM)
Investor: European Union, MSCA Marie Skłodowska-Curie Actions (Excellent Science)
PrintDisplayed: 22/8/2024 05:20